Treatment sequencing considerations when selecting a first DMT
In this presentation, Dr Arun discusses data from the real-world GLIMPSE study, and from MAGNIFY-MS findings at Year 3
Benefit of using IRTs early in the MS treatment algorithm
In this presentation, Dr Rau highlights treatment options for patients with RMSa, and presents data from the MAGNIFY-MS substudy on B-cell counts in patients treated with MAVENCLAD®
Practical considerations when switching is required
In this presentation, Dr Domínguez discusses data from the Phase 4 CLAD CROSS study, the 12-month interim analysis of CLICK-MS study, and switching outcomes from Komodo Database, US
Real-world experience with MAVENCLAD® in an older population
In this presentation, Dr Negroski highlights data on the effects of MAVNECLAD® on older patients from a post hoc analysis of the CLARITY study and RWE from Switzerland and Italy
Switching from other high efficacy DMTs to MAVENCLAD®
In this presentation, Dr Hughes discusses MAVENCLAD® data from the CLADRINA study, a US real-world cohort, and presents cognition data from MAGNIFY-MS
Switching from other high efficacy DMTs to MAVENCLAD®
In this presentation, Dr Hughes discusses MAVENCLAD® data from the CLADRINA study, a US real-world cohort, and presents cognition data from MAGNIFY-MS
Welcome to Merck Healthcare!
Help us direct you to the right information by selecting one of the following options:
